Startseite>>Signaling Pathways>> Microbiology & Virology>> HCV>>Valopicitabine dihydrochloride

Valopicitabine dihydrochloride (Synonyms: NM283 dihydrochloride)

Katalog-Nr.GC63635

Valopicitabin (NM283) Dihydrochlorid ist ein Nukleosid-Analogon und das oral bioverfÜgbare Prodrug des potenten Anti-HCV-Wirkstoffs 2'-C-Methylcytidin (NM107).

Products are for research use only. Not for human use. We do not sell to patients.

Valopicitabine dihydrochloride Chemische Struktur

Cas No.: 640725-71-9

Größe Preis Lagerbestand Menge
5 mg
387,00 $
Auf Lager
10 mg
612,00 $
Auf Lager
25 mg
1.170,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Valopicitabine (NM283) dihydrochloride is a nucleoside analog and the orally bioavailable prodrug of the potent anti-HCV agent 2’-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination[1][2].

Valopicitabine (NM283) (100 mg/kg; oral administration; Sprague-Dawley Rats) dihydrochloride shows the Cmax, AUC, t1/2, and tmax were 3.624 μg/mL, 8.95 μg h/mL, 0.64 hours and 1 hour, respectively[2].

[1]. Liu-Young G, et al. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDS. 2008;22(6):449-457.
[2]. Pierra C, et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2’-C-methylcytidine. J Med Chem. 2006;49(22):6614-6620.

Bewertungen

Review for Valopicitabine dihydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Valopicitabine dihydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.